Translating Gene Discovery Efforts Into Primary Prevention and Drug Discovery

Translating Gene Discovery Efforts Into Primary Prevention and Drug Discovery

July 16, 2015

Address

727 E. Tyler St.
Tempe, AZ 85287

Location

Biodesign Institute, Auditorium B105

Date and Time

July 31, 2015, 2:30 pm (Length: 0 hour 0 minutes)

iCal Download


Presented by Philip De Jager, M.D., Ph.D., Steven R. and Kathleen P. Haley Distinguished Chair for the Neurosciences; Director for Basic and Translational Research, Institute for the Neurosciences in the Departments of Neurology and Psychiatry, Brigham & Women's Hospital

Using multiple sclerosis as an example, we will discuss how to leverage genetic and epidemiologic risk factors to drive a novel generation of human studies to understand the transition from health to disease. Our Genes & Environment in MS study puts us on a clear path towards primary prevention and offers a platform for the execution of prevention trials. Using Alzheimer's disease, we will discuss how genetic insights, coupled with deep characterization of the target organ with multiple levels of "omic" data, can lead to the generation of molecular networks that are an ideal substrate for target identification and validation. Funded through the Accelerating Medicines Partnership program, our group is implementing this program of investigation using validation in different model systems such as iPSC-derived neurons and monocyte-derived microglial-like cells to identify novellead compounds for AD.